Please find attached Audited Financial Results for Quarter and year ended on 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Ltd reported audited results for FY25 with no revenue from core sales, only Rs. 54 lakh in other operating income, flat versus FY24. Total income stood at Rs. 54.22 lakh (FY24: Rs. 54.35 lakh). Profit after tax rose modestly to Rs. 20.09 lakh from Rs. 18.91 lakh in FY24, while EPS improved to Rs. 0.1992 from Rs. 0.1875. The company has no borrowings and operating cash flow of Rs. 24.35 lakh. Other equity remains negative at Rs. (65.00) lakh due to accumulated losses, though total equity is positive at Rs. 943.37 lakh supported by share capital. The statutory auditor (Dipal R. Shah & Co.) issued an unmodified opinion with no qualifications.
Shareholders should note the company has no active sales operations and its profitability relies entirely on other operating income, which may not be sustainable. The negative reserves and stagnant top line raise questions about long-term business viability, despite the unqualified audit opinion.